Get the Stockscreener App
479.79
1.11%
5.29
After Hours:
479.70
-0.09
-0.02%
Vertex Pharmaceuticals Inc stock is traded at $479.79, with a volume of 2.36M.
It is up +1.11% in the last 24 hours and up +3.92% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$474.50
Open:
$479.9
24h Volume:
2.36M
Relative Volume:
1.55
Market Cap:
$123.21B
Revenue:
$11.02B
Net Income/Loss:
$-535.60M
P/E Ratio:
-218.09
EPS:
-2.2
Net Cash Flow:
$-978.00M
1W Performance:
-0.92%
1M Performance:
+3.92%
6M Performance:
-3.25%
1Y Performance:
+14.03%
1-Day Range:
$474.01
$484.98
1-Week Range:
$473.51
$487.50
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Acima Private Wealth LLC - MarketBeat
FourThought Financial Partners LLC Takes $279,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Mutual of America Capital Management LLC Has $13.25 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Flputnam Investment Management Co. Purchases 22,141 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
QRG Capital Management Inc. Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Illinois Municipal Retirement Fund Has $19.08 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Longbow Finance SA Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Y Intercept Hong Kong Ltd Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
ARK Investment Management LLC Sells 25,749 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
National Pension Service Increases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
582 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by World Equity Group Inc. - MarketBeat
Vertex Pharmaceuticals EVP Tatsis sells $251,930 in stock - Investing.com
Vertex Pharmaceuticals’ EVP sells $1.26m in stock - Investing.com
Vertex Pharmaceuticals exec sells $610,560 in stock - Investing.com
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug - MSN
Vertex Pharma win EU backing for Kaftrio (VRTX:NASDAQ) - Seeking Alpha
Could 4,000 More CF Patients Soon Access Vertex's KAFTRIO? EU Regulators Say Yes - StockTitan
Generali Investments Towarzystwo Funduszy Inwestycyjnych Makes New $483,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Peloton Wealth Strategists Acquires 3,859 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Oppenheimer Asset Management Inc. Sells 2,862 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Nwam LLC Grows Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by IFP Advisors Inc - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by HealthInvest Partners AB - MarketBeat
BankPlus Trust Department Buys Shares of 1,379 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Sionna Therapeutics’ NBD1 stabilisers hold potential to differentiate from Vertex’s existing therapies in cystic fibrosis: GlobalData - Express Pharma
Vertex Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
ING Groep NV Has $1.93 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Severs Liver Gene Therapies Partnership With Verve - BioSpace
Vertex exits liver disease gene editing pact with Verve - FirstWord Pharma
Vertex ends gene editing research pact with Verve - BioPharma Dive
Biopharmaceutical index drops in 2024, but starts new year on a rebound - BioWorld Online
Verve is latest gene editing company to suffer setback, as Vertex walks away from pact - Endpoints News
Vertex axes Verve gene editing pact amid shift in R&D priorities - Fierce Biotech
Proficio Capital Partners LLC Grows Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Gulf International Bank UK Ltd Sells 916 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by NewEdge Wealth LLC - MarketBeat
Ipswich Investment Management Co. Inc. Has $2.02 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Insider Sell: Kristen Ambrose Sells Shares of Vertex Pharmaceuti - GuruFocus.com
Vertex Pharmaceuticals EVP sells $849,838 in stock By Investing.com - Investing.com Australia
Vertex Pharmaceuticals EVP sells $849,838 in stock - Investing.com
Vertex Pharmaceuticals EVP sells $170k of stock - Investing.com India
Vertex Pharmaceuticals exec David Altshuler sells $407k in stock - Investing.com
Vertex Pharmaceuticals’ SWOT analysis: stock outlook mixed as CF leader faces 2025 hurdles - Investing.com
14,331 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Fisher Funds Management LTD - MarketBeat
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller - MSN
Bray Capital Advisors Grows Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Is Vertex Pharmaceuticals Gaining or Losing Market Support? - Benzinga
Astrazeneca, Vertex, Axsome secure US FDA approvals in January - BioWorld Online
VRTX stock analysis: what you need to know about Vertex? - Markets.com
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - MSN
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vertex Pharmaceuticals Inc Stock (VRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. |
Feb 27 '25 |
Sale |
475.34 |
2,650 |
1,259,651 |
19,352 |
| ALTSHULER DAVID | EVP, Chief Scientific Officer |
Feb 27 '25 |
Sale |
480.00 |
1,272 |
610,560 |
32,974 |
0.57%
4.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):